Why a guideline can list a regimen before a phase 3 trial reports
In a study of new multiple-myeloma regimens, NCCN listing often preceded reported phase 3 data. That is a description of one guideline history, not evidence that guidelines routinely run ahead of regulators or that all early listings are equally supported.
Written retrospectively and published on August 3, 2026.
Background reading, not clinical guidance. This describes published research; it is not a recommendation for any individual case, and the cited studies may have been superseded.
Randomised phase 3 trials are valuable, but they are not the only information a guideline panel sees. A panel can weigh prospective phase 1 or 2 data, biological rationale, feasibility, safety, unmet need and other evidence while confirmatory trials are still running.
A 2025 study followed 21 regimens newly added to NCCN guidance for newly diagnosed multiple myeloma. The median interval from first prospective clinical data to guideline listing was 15 months. Where phase 3 data later appeared after a listing, the median interval was about three and a half years.
What the study does — and does not — show
The sequence was not universal. Some phase 3 data preceded listing, and four of the 21 regimens still had no phase 3 trial at the study’s cutoff. The analysis looked at a specific disease and a specific guideline history, not every cancer recommendation.
It also did not analyse FDA approval dates. It can support the narrower conclusion that NCCN listing in this setting frequently preceded reported randomised confirmatory data — not the larger claim that guidelines generally precede regulators.
Comments
Threads are public and indexed — please keep personal medical data out of them. Found a clinical error? Open an issue instead.
Comments are not switched on yet — the backend still needs to be configured.